Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Childhood obesity linked to schizophrenia in adulthood: study

Having more than the normal range of body mass index (BMI) in childhood could elevate the risk of developing schizophrenia in adulthood, the study revealed.

Medical Daily

FDA hopes to fight obesity with labels

The agency plans to make a formal proposal in October

Salon

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com

Junk food ads to be banned pre-watershed from next year

Evening Standard

NHS restricting access to obesity services across England, BMJ finds

Budget cuts to local services fell disproportionately on care for obese patients, leading to ‘postcode lottery’

The Guardian - UK

'Removing blame': New weight-loss drug for obesity and overweight people

First there was Ozempic, then Wegovy, now we have Mounjaro.

Newcastle Herald

Read news from The Economist, FT, and more,
with one subscription

Liraglutide: Weight loss drug found to be 'safe and effective' for children aged under 12

Daily injection found to reduce body mass index and improve blood pressure in children between ages of 6 and 12

Evening Standard

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic and Wegovy can supercharge weight loss and even defy ageing – but can they save the NHS?

Analysis: It’s been heralded as the ‘fountain of youth’ that could cure heart problems and promote rapid weight loss, but could Ozempic change all our lives, asks Rebecca Thomas

The Independent UK

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Obesity Raises Risk Of COVID Infection By 34%: Study Says

The study suggests that obesity not only worsens the outcomes of COVID but also increases the risk for infection upon exposure.

Medical Daily

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times

10 Things Americans Love Eating That Are Banned In Other Countries

Consumers in the US put their trust in organizations such as the Food and Drug Administration to keep foods, fish, and livestock safe - but to what standards?

International Business Times UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

The simple sandwich filler linked with a 15% higher risk of type 2 diabetes

Researchers say the findings back the recommendations to reduce meat intake

Salon

Support for processed food taxes grows

Participants of a survey conducted by Ipsos said the taxes would help combat the country’s obesity crisis

The Independent UK

Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

Fortune

Here's the real reason Ozempic-like weight-loss drugs are so popular

Cohorts who were unresponsive to previous strategies like portion control may be responding to the new GLP 1 drugs.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Majority in UK want new tax on makers of ultra-processed and junk food

Exclusive: Poll findings prompt calls for ministers to impose sugar tax-style levy on companies to combat obesity

Fortune

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

The Guardian - UK

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Conversation

Sarcopenic obesity can rob people of their strength – but even brief bursts of exercise help a lot

It’s no secret old age can rob us of our strength. This age-related muscle wastage – known as sarcopenia – can eventually lead to more falls, more hospital stays, difficulty with walking or toileting and less independence. Eventually, it can mean needing residential aged care.

Bored Panda

“We’re In The ‘Ozempic Era'”: Plus-Size Model Calls For Self-Acceptance After Joining SI Cover

"We're in the Ozempic era," says plus-size supermodel Hunter McGrady, the new cover woman for 2024 Sports Illustrated Swimsuit. The post “We’re In The ‘Ozempic Era'”: Plus-Size Model Calls For Self-Acceptance After Joining SI Cover first appeared on Bored Panda.

Salon

Cancer rates rise for Gen X, Millenials

Cancer rates in Millennials and Gen X have risen sharply along with obesity rates

Fortune

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.